Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of eucommia ulmoides lignan extract in preparing PPARalpha agonist

A technology of high triglyceride and Eucommia lignan, which is applied in the field of medicine

Active Publication Date: 2015-04-15
CHANGSHA DUXACT BIOTECH CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Application number: 200710035744.7 discloses the application of eucommia lignans and its extracts in anti-cardiovascular remodeling, and the new application of eucommia lignans extracts needs to be further studied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of eucommia ulmoides lignan extract in preparing PPARalpha agonist
  • Application of eucommia ulmoides lignan extract in preparing PPARalpha agonist
  • Application of eucommia ulmoides lignan extract in preparing PPARalpha agonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] The preparation of embodiment 1 eucommia lignan extract

[0038] Take 2Kg of bark of Eucommia ulmoides (with the outer skin removed), extract twice with 8L of 65% ethanol under reflux, each time for 1h, filter, combine the two extracts and concentrate to 800ml. Mix and load the sample with D101 macroporous resin (column volume of macroporous resin is 3 L), wash with water for 3 times of column volume, continue to wash with 1% ammonia water for 3 times of column volume, and then wash with water until neutral. Elute with 20% ethanol for 2 column volumes and 45% ethanol for 2.5 column volumes. The 45% ethanol eluate was concentrated to 600ml. The eluate was concentrated and dried to a powder. Using pinoresinol diglucoside as a control, the lignan content of Eucommia ulmoides lignan extract was 85% by ultraviolet detection, and the content of pinoresinol diglucoside by HPLC was 12.5%.

Embodiment 2

[0039] The preparation of embodiment 2 eucommia lignan extract

[0040] After the bark of Eucommia ulmoides was crushed, 9 L of 60% ethanol was added to reflux for extraction for 1 h, filtered, and the filter residue was extracted with 7 L of 60% ethanol for 1 h, filtered, the two extracts were combined, and concentrated until there was no alcohol smell to obtain a concentrated solution of about 3 L. The concentrated solution was passed through the AB-8 macroporous adsorption resin column, firstly eluted with 5L of water, then 7L of 60% ethanol, collected the 60% ethanol eluate, concentrated to 150ml, slowly added to 450ml of water, filtered, concentrated, A dry solid powder was obtained. Using pinoresinol diglucoside as a control, the lignan content of Eucommia ulmoides lignan extract was 51% detected by ultraviolet light, and the content of pinoresinol diglucoside detected by HPLC was 3.5%.

Embodiment 3

[0042] The eucommia lignan extracts obtained in Example 1 and Example 2 were used in the experimental research of lowering triglyceride and the experimental research of activating PPARα in Example 3.

[0043] 1. Experimental study on the reduction of triglycerides by eucommia lignan extracts

[0044] 1.1 Experimental method

[0045] 1.1.1 Cell culture and grouping:

[0046] a) Culture HepG2 cells (37°C, 5% CO2) with DMEM high-glucose medium (containing 10% fetal bovine serum);

[0047] b) HepG 2 was inoculated in a 6-well plate at a certain density of 5000 / mL, 1 ml / well, and cultured with DMEM high-glucose medium (containing 10% fetal bovine serum);

[0048] c) When the cells were inoculated for 24 hours, the old medium was discarded, and DMEM low-sugar medium (containing 0.5 mM oleic acid, 10% fetal bovine serum) was added for cultivation, and the normal group was cultivated with DMEM low-sugar medium (containing 10% fetal bovine serum). Continue culturing for 24 hours to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, particularly provides application of an eucommia ulmoides lignan extract in preparing a PPARalpha agonist, and in particular relates to the application of the eucommia ulmoides lignan extract in preparing a drug for preventing and treating hyperlipemia. Lignan in the eucommia ulmoides lignan extract accounts for 30%-90% of the total weight of the eucommia ulmoides lignan extract; and the content of the effective constituent pinoresinol diglucoside in the lignan accounts for 1%-15% of the total weight of the eucommia ulmoides lignan extract.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a new application of eucommia lignan extract. Background technique [0002] Hyperlipidemia (hypercholesterolemia and / or hypertriglyceridemia) is a common blood lipid disorder and an independent risk factor for atherosclerosis, coronary heart disease, acute myocardial infarction, stroke and other diseases. Clinical studies have confirmed that statins reduce plasma cholesterol levels, thereby reducing the incidence of various cardiovascular diseases and the mortality and disability rates. [0003] Recent studies have shown that some patients with dyslipidemia still face residual cardiovascular risk even after intensive cholesterol-lowering treatment with high-dose statins, especially those with type 2 diabetes, obesity and metabolic syndrome. ) is one of the main risk factors for residual cardiovascular risk. [0004] At present, there are few types of drugs targeted at controll...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/46A61P3/06A61K129/00
Inventor 李慧李振宇严谨姜德建胡凯郭成贤周宏灏欧阳冬生
Owner CHANGSHA DUXACT BIOTECH CO LTD